Campo E, Jaffe ES, Cook JR et al (2022) The International Consensus Classification of Mature Lymphoid Neoplasms: a report from the Clinical Advisory Committee. Blood 140:1229–1253. https://doi.org/10.1182/BLOOD.2022015851

Article  PubMed  PubMed Central  CAS  Google Scholar 

Alaggio R, Amador C, Anagnostopoulos I et al (2022) The 5th edition of the World Health Organization Classification of haematolymphoid tumours: lymphoid neoplasms. Leukemia 36:1720–1748

Article  PubMed  PubMed Central  Google Scholar 

Scott DW, King RL, Staiger AM et al (2018) High-grade B-cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements with diffuse large B-cell lymphoma morphology. Blood 131:2060–2064. https://doi.org/10.1182/blood-2017-12-820605

Article  PubMed  PubMed Central  CAS  Google Scholar 

Copie-Bergman C, Cuillière-Dartigues P, Baia M et al (2015) MYC-IG rearrangements are negative predictors of survival in DLBCL patients treated with immunochemotherapy: a GELA/LYSA study. Blood 126:2466–2474

Article  PubMed  CAS  Google Scholar 

Agarwal R, Lade S, Liew D et al (2016) Role of Immunohistochemistry in the era of genetic testing in MYC-positive aggressive B-cell lymphomas: a study of 209 cases. J Clin Pathol 69:266–270. https://doi.org/10.1136/jclinpath-2015-203002

Article  PubMed  CAS  Google Scholar 

Di Napoli A, Remotti D, Agostinelli C et al (2019) A practical algorithmic approach to mature aggressive B cell lymphoma diagnosis in the double/triple hit era: selecting cases, matching clinical benefit. Virchows Arch 475:513–518. https://doi.org/10.1007/s00428-019-02637-2

Article  PubMed  PubMed Central  Google Scholar 

Ambrosio MR, Lazzi S, Lo BG et al (2019) MYC protein expression scoring and its impact on the prognosis of aggressive B-cell lymphoma patients. Haematologica 104:e25–e28. https://doi.org/10.3324/haematol.2018.195958

Article  PubMed  PubMed Central  CAS  Google Scholar 

Kluk MJ, Chapuy B, Sinha P et al (2012) Immunohistochemical detection of MYC-driven diffuse large B-cell lymphomas. PLoS ONE 7:e33813. https://doi.org/10.1371/journal.pone.0033813

Article  PubMed  PubMed Central  CAS  Google Scholar 

Green TM, Nielsen O, De Stricker K et al (2012) High levels of nuclear MYC protein predict the presence of myc rearrangement in diffuse large B-cell lymphoma. Am J Surg Pathol 36:612–619. https://doi.org/10.1097/PAS.0b013e318244e2ba

Article  PubMed  Google Scholar 

Colomo L, Vazquez I, Papaleo N et al (2017) LMO2-negative expression predicts the presence of MYC TRANSLOCATIONS IN AGGRESSIVE B-Cell lymphomas. Am J Surg Pathol 41:877–886. https://doi.org/10.1097/PAS.0000000000000839

Article  PubMed  Google Scholar 

Vazquez I, Papaleo N, Garcia E et al (2020) Clinical interest of LMO2 testing for the diagnosis of aggressive large B-cell lymphomas. Cancers (Basel) 12(4):884. https://doi.org/10.3390/cancers12040884

Article  PubMed  CAS  Google Scholar 

Vazquez I, Papaleo N, Lop J et al (2021) Lack of expression of LMO2 clone SP51 identifies MYC rearrangements in aggressive large B-cell lymphomas. Virchows Arch 479:1073–1078. https://doi.org/10.1007/s00428-021-03091-9

Article  PubMed  CAS  Google Scholar 

Chapman J, Verdun RE, Lossos IS (2021) Low LIM-domain only 2 (LMO2) expression in aggressive B cell lymphoma correlates with MYC and MYC/BCL2 rearrangements, especially in germinal center cell-type tumors. Leuk Lymphoma 62:2547–2550

Article  PubMed  PubMed Central  CAS  Google Scholar 

Liu Y, Bian T, Zhang Y et al (2019) A combination of LMO2 negative and CD38 positive is useful for the diagnosis of Burkitt lymphoma. Diagn Pathol 14:100. https://doi.org/10.1186/s13000-019-0876-3

Article  PubMed  PubMed Central  CAS  Google Scholar 

Papaleo N, Climent F, Tapia G et al (2023) Round-robin testing for LMO2 and MYC as immunohistochemical markers to screen MYC rearrangements in aggressive large B-cell lymphoma. Virchows Arch 485:307–314. https://doi.org/10.1007/s00428-023-03584-9

Article  PubMed  PubMed Central  CAS  Google Scholar 

Hans CP, Weisenburger DD, Greiner TC et al (2004) Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood 103:275–282. https://doi.org/10.1182/blood-2003-05-1545

Article  PubMed  CAS  Google Scholar 

Ventura RA, Martin-Subero JI, Jones M et al (2006) FISH analysis for the detection of lymphoma-associated chromosomal abnormalities in routine paraffin-embedded tissue. J Mol Diagn 8:141–151. https://doi.org/10.2353/jmoldx.2006.050083

Article  PubMed  PubMed Central  CAS  Google Scholar 

Zweig MH, Campbell G (1993) Receiver-operating characteristic (ROC) plots: a fundamental evaluation tool in clinical medicine. Clin Chem 39:561–577. https://doi.org/10.1093/clinchem/39.4.561

Article  PubMed  CAS  Google Scholar 

McGee S (2002) Simplifying likelihood ratios. J Gen Intern Med 17:646–649. https://doi.org/10.1046/j.1525-1497.2002.10750.x

Article  PubMed  Google Scholar 

Falini B, Martino G, Lazzi S (2023) A comparison of the International Consensus and 5th World Health Organization classifications of mature B-cell lymphomas. Leukemia 37:18–34. https://doi.org/10.1038/s41375-022-01764-1

Article  PubMed  Google Scholar 

Alduaij W, Collinge B, Ben-Neriah S et al (2023) Molecular determinants of clinical outcomes in a real-world diffuse large B-cell lymphoma population. Blood 141:2493–2507. https://doi.org/10.1182/blood.2022018248

Article  PubMed  CAS  Google Scholar 

Jin Z, May WS, Gao F et al (2006) Bcl2 suppresses DNA repair by enhancing c-Myc transcriptional activity. J Biol Chem 281:14446–14456. https://doi.org/10.1074/jbc.M511914200

Article  PubMed  CAS  Google Scholar 

Parvin S, Ramirez-Labrada A, Aumann S et al (2019) LMO2 Confers synthetic lethality to PARP inhibition in DLBCL. Cancer Cell 36:237-249.e6. https://doi.org/10.1016/j.ccell.2019.07.007

Article  PubMed  PubMed Central  CAS  Google Scholar 

Papaleo N, Molina-Alvarez A, Onieva R et al (2024) Chromogenic LMO2 mRNA ISH expression correlates with LMO2 protein and gene expression and captures their survival impact in diffuse large B-Cell lymphoma. NOS Cancers (Basel) 16:2378. https://doi.org/10.3390/cancers16132378

Article  PubMed  CAS  Google Scholar 

Trevethan R (2017) Sensitivity, specificity, and predictive values: foundations, pliabilities, and pitfalls in research and practice. Front Public Health 5:307. https://doi.org/10.3389/fpubh.2017.00307

Article  PubMed  PubMed Central  Google Scholar 

Sakr H, Cook JR (2019) Identification of “double Hit” lymphomas using updated WHO Criteria: insights from routine MYC immunohistochemistry in 272 consecutive cases of aggressive B-cell lymphomas. Appl Immunohistochem Mol Morphol 27:410–415. https://doi.org/10.1097/PAI.0000000000000657

Article  PubMed  CAS  Google Scholar 

Chisholm KM, Bangs CD, Bacchi CE et al (2015) Expression profiles of MYC protein and MYC gene rearrangement in lymphomas. Am J Surg Pathol 39:294–303. https://doi.org/10.1097/PAS.0000000000000365

Article  PubMed  Google Scholar 

Wang XJ, Medeiros LJ, Lin P et al (2015) MYC cytogenetic status correlates with expression and has prognostic significance in patients with MYC/BCL2 protein double-positive diffuse large B-cell lymphoma. Am J Surg Pathol 39:1250–1258. https://doi.org/10.1097/PAS.0000000000000433